Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 114

1.

The Src inhibitor AZD0530 blocks invasion and may act as a radiosensitizer in lung cancer cells.

Purnell PR, Mack PC, Tepper CG, Evans CP, Green TP, Gumerlock PH, Lara PN, Gandara DR, Kung HJ, Gautschi O.

J Thorac Oncol. 2009 Apr;4(4):448-54. doi: 10.1097/JTO.0b013e31819c78fb.

2.

Bortezomib plus gemcitabine/carboplatin as first-line treatment of advanced non-small cell lung cancer: a phase II Southwest Oncology Group Study (S0339).

Davies AM, Chansky K, Lara PN Jr, Gumerlock PH, Crowley J, Albain KS, Vogel SJ, Gandara DR; Southwest Oncology Group.

J Thorac Oncol. 2009 Jan;4(1):87-92. doi: 10.1097/JTO.0b013e3181915052.

3.

Impairment of the DNA repair and growth arrest pathways by p53R2 silencing enhances DNA damage-induced apoptosis in a p53-dependent manner in prostate cancer cells.

Devlin HL, Mack PC, Burich RA, Gumerlock PH, Kung HJ, Mudryj M, deVere White RW.

Mol Cancer Res. 2008 May;6(5):808-18. doi: 10.1158/1541-7786.MCR-07-2027.

4.

Schedule-dependent apoptosis in K-ras mutant non-small-cell lung cancer cell lines treated with docetaxel and erlotinib: rationale for pharmacodynamic separation.

Mahaffey CM, Davies AM, Lara PN Jr, Pryde B, Holland W, Mack PC, Gumerlock PH, Gandara DR.

Clin Lung Cancer. 2007 Nov;8(9):548-53.

PMID:
18186959
5.

The proteasome inhibitor bortezomib in combination with gemcitabine and carboplatin in advanced non-small cell lung cancer: a California Cancer Consortium Phase I study.

Davies AM, Ruel C, Lara PN, Lau DH, Gumerlock PH, Bold R, Shibata S, Lenz HJ, Schenkein DP, Gandara DR.

J Thorac Oncol. 2008 Jan;3(1):68-74. doi: 10.1097/JTO.0b013e31815e8b88.

6.

Origin and prognostic value of circulating KRAS mutations in lung cancer patients.

Gautschi O, Huegli B, Ziegler A, Gugger M, Heighway J, Ratschiller D, Mack PC, Gumerlock PH, Kung HJ, Stahel RA, Gandara DR, Betticher DC.

Cancer Lett. 2007 Sep 8;254(2):265-73. Epub 2007 Apr 20.

PMID:
17449174
7.

Bortezomib (PS-341) in relapsed or refractory extensive stage small cell lung cancer: a Southwest Oncology Group phase II trial (S0327).

Lara PN Jr, Chansky K, Davies AM, Franklin WA, Gumerlock PH, Guaglianone PP, Atkins JN, Farneth N, Mack PC, Crowley JJ, Gandara DR.

J Thorac Oncol. 2006 Nov;1(9):996-1001.

8.

Bortezomib plus docetaxel in advanced non-small cell lung cancer and other solid tumors: a phase I California Cancer Consortium trial.

Lara PN Jr, Koczywas M, Quinn DI, Lenz HJ, Davies AM, Lau DH, Gumerlock PH, Longmate J, Doroshow JH, Schenkein D, Kashala O, Gandara DR.

J Thorac Oncol. 2006 Feb;1(2):126-34.

9.

Pharmacodynamic separation of epidermal growth factor receptor tyrosine kinase inhibitors and chemotherapy in non-small-cell lung cancer.

Davies AM, Ho C, Lara PN Jr, Mack P, Gumerlock PH, Gandara DR.

Clin Lung Cancer. 2006 May;7(6):385-8. Review.

PMID:
16800963
10.

Spontaneous immortalization of human epidermal cells with naturally elevated telomerase.

Rea MA, Zhou L, Qin Q, Barrandon Y, Easley KW, Gungner SF, Phillips MA, Holland WS, Gumerlock PH, Rocke DM, Rice RH.

J Invest Dermatol. 2006 Nov;126(11):2507-15. Epub 2006 Jun 15.

11.

Gefitinib therapy in advanced bronchioloalveolar carcinoma: Southwest Oncology Group Study S0126.

West HL, Franklin WA, McCoy J, Gumerlock PH, Vance R, Lau DH, Chansky K, Crowley JJ, Gandara DR.

J Clin Oncol. 2006 Apr 20;24(12):1807-13.

PMID:
16622257
12.

A randomized phase II trial of the matrix metalloproteinase inhibitor BMS-275291 in hormone-refractory prostate cancer patients with bone metastases.

Lara PN Jr, Stadler WM, Longmate J, Quinn DI, Wexler J, Van Loan M, Twardowski P, Gumerlock PH, Vogelzang NJ, Vokes EE, Lenz HJ, Doroshow JH, Gandara DR.

Clin Cancer Res. 2006 Mar 1;12(5):1556-63.

13.

Therapeutic strategies for combined-modality therapy of locally advanced non-small-cell lung cancer: rationale for consolidation docetaxel therapy.

Gandara DR, Vallières E, Gaspar LE, Kelly K, Albain KS, Herbst RS Jr, Lara PN Jr, Mack P, Gumerlock PH, Crowley JJ.

Clin Lung Cancer. 2005 Dec;7 Suppl 3:S93-7. Review.

PMID:
16384543
14.

Proteasome inhibition in small-cell lung cancer: preclinical rationale and clinical applications.

Lara PN Jr, Bold RJ, Mack PC, Davies AM, Gumerlock PH, Gandara DR.

Clin Lung Cancer. 2005 Oct;7 Suppl 2:S67-71. Review.

PMID:
16250931
15.

Bortezomib-based combinations in the treatment of non-small-cell lung cancer.

Davies AM, Lara PN Jr, Mack PC, Gumerlock PH, Bold RJ, Gandara DR.

Clin Lung Cancer. 2005 Oct;7 Suppl 2:S59-63. Review.

PMID:
16250929
16.

Epidermal growth factor receptor tyrosine kinase inhibitors plus chemotherapy: case closed or is the jury still out?

Gandara DR, Gumerlock PH.

J Clin Oncol. 2005 Sep 1;23(25):5856-8. Epub 2005 Jul 25. No abstract available.

PMID:
16043825
17.

The cyclin-dependent kinase inhibitor UCN-01 plus cisplatin in advanced solid tumors: a California cancer consortium phase I pharmacokinetic and molecular correlative trial.

Lara PN Jr, Mack PC, Synold T, Frankel P, Longmate J, Gumerlock PH, Doroshow JH, Gandara DR.

Clin Cancer Res. 2005 Jun 15;11(12):4444-50.

18.

A phase II study of flavopiridol in patients with advanced renal cell carcinoma: results of Southwest Oncology Group Trial 0109.

Van Veldhuizen PJ, Faulkner JR, Lara PN Jr, Gumerlock PH, Goodwin JW, Dakhil SR, Gross HM, Flanigan RC, Crawford ED; Southwest Oncology Group.

Cancer Chemother Pharmacol. 2005 Jul;56(1):39-45. Epub 2005 Mar 25.

PMID:
15791454
19.

Glycogen synthesis correlates with androgen-dependent growth arrest in prostate cancer.

Schnier JB, Nishi K, Gumerlock PH, Gorin FA, Bradbury EM.

BMC Urol. 2005 Mar 24;5:6.

20.

Intermittent dosing of the farnesyl transferase inhibitor tipifarnib (R115777) in advanced malignant solid tumors: a phase I California Cancer Consortium Trial.

Lara PN Jr, Law LY, Wright JJ, Frankel P, Twardowski P, Lenz HJ, Lau DH, Kawaguchi T, Gumerlock PH, Doroshow JH, Gandara DR.

Anticancer Drugs. 2005 Mar;16(3):317-21.

PMID:
15711184
21.

Enhancement of radiation cytotoxicity by UCN-01 in non-small cell lung carcinoma cells.

Mack PC, Jones AA, Gustafsson MH, Gandara DR, Gumerlock PH, Goldberg Z.

Radiat Res. 2004 Dec;162(6):623-34.

PMID:
15548112
22.

Gemcitabine in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy: a phase II California cancer consortium trial.

Lara PN Jr, Gumerlock PH, Mack PC, Lau DH, Gandour-Edwards R, Edelman MJ, Albain KS, Law LY, Longmate J, Frankel P, Reddy GP, Israel V, Doroshow JH, Gandara DR.

Clin Lung Cancer. 2004 Sep;6(2):102-7.

PMID:
15476595
23.

Abnormalities of apoptotic and cell cycle regulatory proteins in distinct histopathologic components of benign prostatic hyperplasia.

Gandour-Edwards R, Mack PC, Devere-White RW, Gumerlock PH.

Prostate Cancer Prostatic Dis. 2004;7(4):321-6.

PMID:
15314639
24.

Mutant DNA in plasma of lung cancer patients: potential for monitoring response to therapy.

Kimura T, Holland WS, Kawaguchi T, Williamson SK, Chansky K, Crowley JJ, Doroshow JH, Lenz HJ, Gandara DR, Gumerlock PH.

Ann N Y Acad Sci. 2004 Jun;1022:55-60.

PMID:
15251940
25.

Bronchioloalveolar carcinoma: a model for investigating the biology of epidermal growth factor receptor inhibition.

Gandara DR, West H, Chansky K, Davies AM, Lau DH, Crowley J, Gumerlock PH, Hirsch FR, Franklin WA.

Clin Cancer Res. 2004 Jun 15;10(12 Pt 2):4205s-4209s. Review.

26.

Trastuzumab plus docetaxel in HER-2/neu-positive prostate carcinoma: final results from the California Cancer Consortium Screening and Phase II Trial.

Lara PN Jr, Chee KG, Longmate J, Ruel C, Meyers FJ, Gray CR, Edwards RG, Gumerlock PH, Twardowski P, Doroshow JH, Gandara DR.

Cancer. 2004 May 15;100(10):2125-31.

27.

Survival and cell cycle kinetics of human prostate cancer cell lines after single- and multifraction exposures to ionizing radiation.

Scott SL, Gumerlock PH, Beckett L, Li Y, Goldberg Z.

Int J Radiat Oncol Biol Phys. 2004 May 1;59(1):219-27.

PMID:
15093919
28.

Blastic mantle cell lymphoma developing concurrently in a patient with chronic myelogenous leukemia and a review of the literature.

Rodler E, Welborn J, Hatcher S, Unger K, Larkin E, Gumerlock PH, Wun T, Richman C.

Am J Hematol. 2004 Apr;75(4):231-8. Review.

29.

Predictive molecular markers: has the time come for routine use in lung cancer?

Davies AM, Mack PC, Lara PN Jr, Lau DH, Danenberg K, Gumerlock PH, Gandara DR.

J Natl Compr Canc Netw. 2004 Mar;2(2):125-31. Review.

PMID:
19777702
30.

Proteasome inhibition with PS-341 (bortezomib) in lung cancer therapy.

Lara PN Jr, Davies AM, Mack PC, Mortenson MM, Bold RJ, Gumerlock PH, Gandara DR.

Semin Oncol. 2004 Feb;31(1 Suppl 1):40-6. Review.

PMID:
14981579
31.

Trastuzumab plus docetaxel in HER2/neu-positive non-small-cell lung cancer: a California Cancer Consortium screening and phase II trial.

Lara PN Jr, Laptalo L, Longmate J, Lau DH, Gandour-Edwards R, Gumerlock PH, Doroshow JH, Gandara DR; California Cancer Consortium.

Clin Lung Cancer. 2004 Jan;5(4):231-6.

PMID:
14967075
32.

Antisense oligonucleotides in the treatment of non-small-cell lung cancer.

Davies AM, Gandara DR, Lara PN Jr, Mack PC, Lau DH, Gumerlock PH.

Clin Lung Cancer. 2003 Jan;4 Suppl 2:S68-73.

PMID:
14720340
33.
34.

SU5416 plus interferon alpha in advanced renal cell carcinoma: a phase II California Cancer Consortium Study with biological and imaging correlates of angiogenesis inhibition.

Lara PN Jr, Quinn DI, Margolin K, Meyers FJ, Longmate J, Frankel P, Mack PC, Turrell C, Valk P, Rao J, Buckley P, Wun T, Gosselin R, Galvin I, Gumerlock PH, Lenz HJ, Doroshow JH, Gandara DR; California Cancer Consortium.

Clin Cancer Res. 2003 Oct 15;9(13):4772-81.

35.

Tirapazamine plus carboplatin and paclitaxel in advanced malignant solid tumors: a california cancer consortium phase I and molecular correlative study.

Lara PN Jr, Frankel P, Mack PC, Gumerlock PH, Galvin I, Martel CL, Longmate J, Doroshow JH, Lenz HJ, Lau DH, Gandara DR.

Clin Cancer Res. 2003 Oct 1;9(12):4356-62.

36.

Integration of the proteasome inhibitor PS-341 (Velcade) into the therapeutic approach to lung cancer.

Mack PC, Davies AM, Lara PN, Gumerlock PH, Gandara DR.

Lung Cancer. 2003 Aug;41 Suppl 1:S89-96. Review.

PMID:
12867067
37.

Current strategies in the management of hormone refractory prostate cancer.

Martel CL, Gumerlock PH, Meyers FJ, Lara PN.

Cancer Treat Rev. 2003 Jun;29(3):171-87. Review.

PMID:
12787712
38.

Cell cycle-dependent potentiation of cisplatin by UCN-01 in non-small-cell lung carcinoma.

Mack PC, Gandara DR, Lau AH, Lara PN Jr, Edelman MJ, Gumerlock PH.

Cancer Chemother Pharmacol. 2003 Apr;51(4):337-48. Epub 2003 Mar 25.

PMID:
12721762
39.

Methods for isolation and genetic analysis of circulating tumor DNA in patient plasma.

Kawaguchi T, Holland WS, Gumerlock PH.

Methods Mol Med. 2003;85:257-62. Review. No abstract available.

PMID:
12710213
40.

Application of a yeast assay to detect functional p53 mutations in archival prostate cancer tissue.

Shi XB, Di Mauro SM, Highshaw R, Deitch AD, Evans CP, Gumerlock PH, deVere White RW.

Cancer Biother Radiopharm. 2002 Dec;17(6):657-64.

PMID:
12537669
41.

BCL2 antisense reduces prostate cancer cell survival following irradiation.

Scott SL, Higdon R, Beckett L, Shi XB, deVere White RW, Earle JD, Gumerlock PH.

Cancer Biother Radiopharm. 2002 Dec;17(6):647-56.

PMID:
12537668
42.

HER-2/neu is overexpressed infrequently in patients with prostate carcinoma. Results from the California Cancer Consortium Screening Trial.

Lara PN Jr, Meyers FJ, Gray CR, Edwards RG, Gumerlock PH, Kauderer C, Tichauer G, Twardowski P, Doroshow JH, Gandara DR.

Cancer. 2002 May 15;94(10):2584-9.

43.

Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer.

Lord RV, Brabender J, Gandara D, Alberola V, Camps C, Domine M, Cardenal F, Sánchez JM, Gumerlock PH, Tarón M, Sánchez JJ, Danenberg KD, Danenberg PV, Rosell R.

Clin Cancer Res. 2002 Jul;8(7):2286-91.

44.

Complex functions of mutant p53 alleles from human prostate cancer.

Shi XB, Nesslinger NJ, Deitch AD, Gumerlock PH, deVere White RW.

Prostate. 2002 Apr 1;51(1):59-72.

PMID:
11920959
45.

Tirapazamine: prototype for a novel class of therapeutic agents targeting tumor hypoxia.

Gandara DR, Lara PN Jr, Goldberg Z, Le QT, Mack PC, Lau DH, Gumerlock PH.

Semin Oncol. 2002 Feb;29(1 Suppl 4):102-9. Review.

PMID:
11894020
46.

BCL2 antisense transcripts decrease intracellular Bcl2 expression and sensitize LNCaP prostate cancer cells to apoptosis-inducing agents.

Shi XB, Gumerlock PH, Muenzer JT, deVere White RW.

Cancer Biother Radiopharm. 2001 Oct;16(5):421-9.

PMID:
11776759
47.

Anaerobic bacteria and intrahepatic stones: detections of Clostridium sp. and Bacteroides fragilis.

Liu Y, Lam K, Tang YJ, Gumerlock PH, Lee DK, Kim MH, Lee SP, Silva J Jr, Leung JW.

Chin Med J (Engl). 2000 Sep;113(9):858-61.

PMID:
11776087
48.

Molecular-clinical correlative studies in non-small cell lung cancer: application of a three-tiered approach.

Gandara DR, Lara PN, Lau DH, Mack P, Gumerlock PH.

Lung Cancer. 2001 Dec;34 Suppl 3:S75-80. Review. No abstract available.

PMID:
11740998
49.

Activity of high-dose toremifene plus cisplatin in platinum-treated non-small-cell lung cancer: a phase II California Cancer Consortium Trial.

Lara PN Jr, Gandara DR, Longmate J, Gumerlock PH, Lau DH, Edelman MJ, Gandour-Edwards R, Mack PC, Israel V, Raschko J, Frankel P, Perez EA, Lenz HJ, Doroshow JH.

Cancer Chemother Pharmacol. 2001 Jul;48(1):22-8.

PMID:
11488520
50.

Apoptosis-related gene and protein expression in human lymphoma xenografts (Raji) after low dose rate radiation using 67Cu-2IT-BAT-Lym-1 radioimmunotherapy.

Kroger LA, DeNardo GL, Gumerlock PH, Xiong CY, Winthrop MD, Shi XB, Mack PC, Leshchinsky T, DeNardo SJ.

Cancer Biother Radiopharm. 2001 Jun;16(3):213-25.

PMID:
11471486

Supplemental Content

Loading ...
Support Center